Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilematovir (JNJ-53718678) in non-hospitalized adults with RSV infection
jRCT2080224803Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Rilematovir 500 mg, Rilematovir 80 mg plus placebo and Placebo (3 arms). Primary endpoints: Antiviral activity: time to first confirmed undetectable RSV viral load and Clinical outcome: time to resolution of key RSV symptoms. Started Jul 2019; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080224803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224803.